(go to content)

Castellano | Euskara | Français | English

 Imagen decorativa
DTB: Vol 30 No 4

Content tools

Share it

  • Meneame
  • Delicious
  • Twitter
  • Google
  • Facebook

Interchage of biosimilar medicines: effective, safe and efficient

Bol Inf Farmacoter Navar. 2022;30 (4):1-20

A biosimilar is a biological medicine that is very similar to another one already marketed in the European Union (EU) whose patent has expired and the differences between which are not clinically significant, in other words do not affect clinical practice. More biosimilars are slowly being developed and, consequently, the experience with their use is increasing. The European Medicines Agency (EMA) considers the biosimilars approved in the EU to be interchangeable, and has signed a statement to reduce the uncertainty regarding interchangeability of biosimilars in clinical practice. The aim of this bulletin is to define the basic concepts, describe the comparability, authorization and interchangeability processes, evaluate the scientific evidence regarding the efficacy, safety and economic impact of the switch, and to describe the current situation of biosimilars in Spain.
Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)











(1) Unit Innovation and Organization
(2) Pharmacy Service University Hospital of Navarre
Navarre Health Service

Government of Navarre

Contact us | Accessibility | Legal notice | Site map